TOP NEWS: US FDA Grants Breakthrough Status To AstraZeneca Treatment
Author: Alliance News
Published On: 04/01/2019
LONDON (Alliance News) - AstraZeneca PLC on Monday said its drug selumetinib has been granted a breakthrough therapy designation in the US for neurofibromatosis type 1.
Neurofibromatosis type 1 is an incurable genetic condition affecting between 1 in 3,000 and 1 in 4,000 people. The disease can cause tumours called plexiform neurofibromas to develop on the the protective layer around the nerves.
These tumours may result in pain, disfigurement, difficulty controlling movement, and breathing problems. They can also become cancerous.
The breakthrough therapy designation applies to the treatment of paediatric patients who are at least three years old that have neurofibromatosis type 1 and plexiform neurofibromas.
Read more here.